CEL-SCI Corp

$4.13 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About CEL-SCI Corp

CEL-SCI Corporation is a clinical-stage biotechnology company. The Company is focused on activating the immune system to fight cancer and infectious diseases. The Company is engaged in research and developing the treatments for cancer and other diseases by using the immune system. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in a pivotal phase III clinical trial. Its Multikine is an investigational immunotherapy under development for the potential treatment of certain head and neck cancers. The Company is using its Ligand Epitope Antigen Presentation System (LEAPS) technology to develop various new drug candidates, CEL-4000 and CEL-2000, as potential rheumatoid arthritis therapeutic treatments. Its product candidates using its LEAPS technology are LEAPS COV-19, CEL-2000, CEL-4000 and DerG-PG275(Cit). The Company is developing an immunotherapy with the potential to treat the coronavirus (COVID-19) using its LEAPS peptide technology.

Stock Analysis

last close $4.21
1-mo return 1%
3-mo return 49.3%
avg daily vol. 330.57T
52-week high 12.9
52-week low 2.49
market cap. $182M
forward pe -
annual div. -
roe -96.7%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 31.8%
baraka

Subscribe now for daily local and international financial news

Subscribe